Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific administrative transaction within a retirement plan rather than general financial performance.
Material Changes
Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK American Depositary Shares), an increase in the notional allocation of ADSs occurred on November 15, 2012. The transaction price was $41.92 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items related to the company's operational strategy or financial health. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Notional allocation increase in the US Retirement Savings Plan for specific directors and connected persons.
- Transaction Date: November 15, 2012.
- Price per ADS: $41.92.
- Participants: Dr M M Slaoui (13 ADSs), Dr K Slaoui (11 ADSs), Mr W C Louv (22 ADSs), Dr D Pulman (38 ADSs), and Mrs D P Connelly (1 ADS).
- Financial Data: No financial performance metrics are included in this specific filing.